Literature DB >> 29113911

Access to care in rare liver diseases: New challenges and new opportunities.

David E J Jones1, Ekkehard Sturm2, Ansgar W Lohse3.   

Abstract

Patients with rare diseases are often disadvantaged, particularly those with rare liver diseases. Reasons for disadvantage include delayed or overlooked diagnosis, lack of local expertise and high-quality care, poor scientific understanding of the disease process and limited therapeutic options. In adult liver disease this can be compounded by prejudices towards patients with liver disease in general, because of a perception (incorrect for all rare liver diseases) that liver disease is lifestyle related and thus "self-inflicted". In paediatric rare liver diseases, such as biliary atresia, optimising outcomes requires a particularly timely diagnosis. Irrespective of patient age, the scientific and medical community must rise to the challenge of advancing our understanding of rare liver disease, searching for more effective and specific therapies, and providing the infrastructure to provide the best care for all patients, infants, children, young and older adults. The European Reference Network for Rare Liver Diseases is an important step in this direction.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Care delivery; Genetic disease; Rare disease; Transitional care

Mesh:

Year:  2017        PMID: 29113911     DOI: 10.1016/j.jhep.2017.11.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

1.  Rare and undiagnosed liver diseases: challenges and opportunities.

Authors:  Luca Fabris; Mario Strazzabosco
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

2.  Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER.

Authors:  Lucas H P Bernts; David E J Jones; Marleen M Kaatee; Ansgar W Lohse; Christoph Schramm; Ekkehard Sturm; Joost P H Drenth
Journal:  Orphanet J Rare Dis       Date:  2019-07-08       Impact factor: 4.123

Review 3.  Clinical management of autoimmune hepatitis.

Authors:  Simon Pape; Christoph Schramm; Tom Jg Gevers
Journal:  United European Gastroenterol J       Date:  2019-08-25       Impact factor: 4.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.